Open Access
Open access

International Journal of Neonatal Screening

MDPI
MDPI
ISSN: 2409515X

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q1
WOS
Q1
Impact factor
4
SJR
1.313
CiteScore
6.7
Categories
Immunology and Microbiology (miscellaneous)
Obstetrics and Gynecology
Pediatrics, Perinatology and Child Health
Areas
Immunology and Microbiology
Medicine
Years of issue
2015-2025
journal names
International Journal of Neonatal Screening
INT J NEONAT SCREEN
Publications
547
Citations
4 857
h-index
29
Top-3 organizations
Top-3 countries
USA (232 publications)
United Kingdom (58 publications)
Netherlands (54 publications)

Most cited in 5 years

Found 
from chars
Publications found: 24792
Corrigendum to ‘OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs’ [Journal of Thoracic Oncology Vol. 19 No. 10S (2024) S28]
Ho C., Soon Y.Y., Nichol A., Robledo K., Sahgal A., Pinkham M., Melosky B., Huang Y., Parmar A., Solomon B., Liu M., Tham I.W., Sacher A., Tey J.C., Menjak I., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC with PD-L1 Expression ≥50%: 5-Year Outcomes of EMPOWER-Lung 1
Kilickap S., Baramidze A., Sezer A., Özgüroğlu M., Gumus M., Bondarenko I., Gogishvili M., Nechaeva M., Schenker M., Cicin I., Fuang H.G., Kulyaba Y., Zyuhal K., Scheusan R., Garassino M.C., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Gut Microbiota in Advanced Non-small-cell Lung Cancer Receiving Chemo-immunotherapy: An Ancillary Biomarker Study from the Phase III trial JCOG2007 (NIPPON)
Hakozaki T., Tanaka K., Shiraishi Y., Sekino Y., Mitome N., Okuma Y., Aiba T., Utsumi T., Tanizaki J., Azuma K., Hara S., Morita R., Niho S., Yokoyama T., Toyozawa R., et. al.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Selective depletion of CCR8+Treg cells enhances anti-tumor immunity of cytotoxic T cells in lung cancer via dendritic cells
Chen P., Wang H., Tang Z., Shi J., Cheng L., Zhao C., Li X., Zhou C.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reply to: “AI Technologies for Patients With Immune-Related Adverse Events”
O’Reilly D., O’Leary C., Naidoo J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
In this issue
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Navigating the Complexity of Cerebral Prophylaxis: A Path Worth Taking?
Ramella S., Fiore M., D’Angelillo R.M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Reducing pERKs to Break “RAS”istance to Sotorasib
Gray S.G., O’Connor D., Mutti L., Meirson T.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Predictive Biomarker for SCLC Therapeutics: A Broken Promise or a Complex Disease With Missing Links
Chu Q.S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Enlarging the Reach of Screening and Early Detection of Lung Cancer
Brown M., Myers R., Lam S.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
A Response to the Letter to the Editor: “Reply to Lei Wu et al.”
Kim E.K., Bak M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Accurate Risk Factors of Cardiotoxicity in Patients With NSCLC Treated With Osimertinib
Wu L., Liu N., Sun M.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0
Patients With Resectable NSCLC Undergoing Neoadjuvant Chemoimmunotherapy: To Adjuvant or Not to Adjuvant?
Wu P., Li D., Zhang C., Sun N., He J.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 1
Artificial Intelligence Technologies for Managing High-Risk Patients With Immune-Related Adverse Events and Optimizing Timing
Liu F., Li H.
Q1
Elsevier
Journal of Thoracic Oncology 2025 citations by CoLab: 0

Top-100

Citing journals

200
400
600
800
1000
1200
Show all (70 more)
200
400
600
800
1000
1200

Citing publishers

200
400
600
800
1000
1200
1400
1600
Show all (70 more)
200
400
600
800
1000
1200
1400
1600

Publishing organizations

5
10
15
20
25
Show all (70 more)
5
10
15
20
25

Publishing organizations in 5 years

2
4
6
8
10
12
14
16
18
20
Show all (70 more)
2
4
6
8
10
12
14
16
18
20

Publishing countries

50
100
150
200
250
USA, 232, 42.41%
United Kingdom, 58, 10.6%
Netherlands, 54, 9.87%
Germany, 41, 7.5%
Italy, 32, 5.85%
Switzerland, 28, 5.12%
Australia, 26, 4.75%
Japan, 24, 4.39%
France, 21, 3.84%
Canada, 21, 3.84%
Sweden, 20, 3.66%
China, 17, 3.11%
Spain, 14, 2.56%
New Zealand, 14, 2.56%
Denmark, 10, 1.83%
Austria, 9, 1.65%
Philippines, 9, 1.65%
India, 8, 1.46%
Russia, 7, 1.28%
Belgium, 7, 1.28%
Brazil, 7, 1.28%
Portugal, 6, 1.1%
Norway, 6, 1.1%
Finland, 6, 1.1%
Czech Republic, 6, 1.1%
Indonesia, 5, 0.91%
Qatar, 4, 0.73%
Slovakia, 4, 0.73%
Israel, 3, 0.55%
Ireland, 3, 0.55%
Malta, 3, 0.55%
Nigeria, 3, 0.55%
North Macedonia, 3, 0.55%
Slovenia, 3, 0.55%
Thailand, 3, 0.55%
Jamaica, 3, 0.55%
Bulgaria, 2, 0.37%
Hungary, 2, 0.37%
Iceland, 2, 0.37%
Cyprus, 2, 0.37%
Latvia, 2, 0.37%
Lebanon, 2, 0.37%
Mexico, 2, 0.37%
Mongolia, 2, 0.37%
Poland, 2, 0.37%
Saudi Arabia, 2, 0.37%
Serbia, 2, 0.37%
Turkey, 2, 0.37%
Croatia, 2, 0.37%
Kazakhstan, 1, 0.18%
Ukraine, 1, 0.18%
Estonia, 1, 0.18%
Albania, 1, 0.18%
Antigua and Barbuda, 1, 0.18%
Argentina, 1, 0.18%
Armenia, 1, 0.18%
Bosnia and Herzegovina, 1, 0.18%
Vietnam, 1, 0.18%
Guadeloupe, 1, 0.18%
Greece, 1, 0.18%
Georgia, 1, 0.18%
Iran, 1, 0.18%
Cambodia, 1, 0.18%
Colombia, 1, 0.18%
Cuba, 1, 0.18%
Kuwait, 1, 0.18%
Lithuania, 1, 0.18%
Luxembourg, 1, 0.18%
Malawi, 1, 0.18%
Morocco, 1, 0.18%
Moldova, 1, 0.18%
Nepal, 1, 0.18%
Pakistan, 1, 0.18%
Romania, 1, 0.18%
Singapore, 1, 0.18%
Suriname, 1, 0.18%
Tanzania, 1, 0.18%
Trinidad and Tobago, 1, 0.18%
Uzbekistan, 1, 0.18%
Faroe Islands, 1, 0.18%
Montenegro, 1, 0.18%
Chile, 1, 0.18%
South Africa, 1, 0.18%
Kosovo, 1, 0.18%
Show all (54 more)
50
100
150
200
250

Publishing countries in 5 years

20
40
60
80
100
120
140
160
180
200
USA, 182, 44.83%
United Kingdom, 41, 10.1%
Netherlands, 39, 9.61%
Italy, 27, 6.65%
Japan, 22, 5.42%
Germany, 21, 5.17%
Australia, 18, 4.43%
Canada, 17, 4.19%
Switzerland, 15, 3.69%
France, 14, 3.45%
Sweden, 14, 3.45%
China, 13, 3.2%
Spain, 9, 2.22%
New Zealand, 9, 2.22%
Philippines, 9, 2.22%
Austria, 8, 1.97%
India, 7, 1.72%
Russia, 6, 1.48%
Norway, 6, 1.48%
Brazil, 5, 1.23%
Czech Republic, 5, 1.23%
Portugal, 4, 0.99%
Belgium, 4, 0.99%
Denmark, 4, 0.99%
Indonesia, 4, 0.99%
Slovenia, 3, 0.74%
Finland, 3, 0.74%
Bulgaria, 2, 0.49%
Hungary, 2, 0.49%
Ireland, 2, 0.49%
Latvia, 2, 0.49%
Lebanon, 2, 0.49%
Mexico, 2, 0.49%
Mongolia, 2, 0.49%
Poland, 2, 0.49%
Saudi Arabia, 2, 0.49%
Serbia, 2, 0.49%
Slovakia, 2, 0.49%
Thailand, 2, 0.49%
Turkey, 2, 0.49%
Croatia, 2, 0.49%
Jamaica, 2, 0.49%
Kazakhstan, 1, 0.25%
Ukraine, 1, 0.25%
Estonia, 1, 0.25%
Albania, 1, 0.25%
Antigua and Barbuda, 1, 0.25%
Argentina, 1, 0.25%
Armenia, 1, 0.25%
Bosnia and Herzegovina, 1, 0.25%
Vietnam, 1, 0.25%
Greece, 1, 0.25%
Georgia, 1, 0.25%
Israel, 1, 0.25%
Iran, 1, 0.25%
Iceland, 1, 0.25%
Cambodia, 1, 0.25%
Qatar, 1, 0.25%
Cyprus, 1, 0.25%
Colombia, 1, 0.25%
Kuwait, 1, 0.25%
Lithuania, 1, 0.25%
Luxembourg, 1, 0.25%
Malta, 1, 0.25%
Morocco, 1, 0.25%
Moldova, 1, 0.25%
Pakistan, 1, 0.25%
Romania, 1, 0.25%
North Macedonia, 1, 0.25%
Singapore, 1, 0.25%
Suriname, 1, 0.25%
Tanzania, 1, 0.25%
Uzbekistan, 1, 0.25%
Montenegro, 1, 0.25%
Chile, 1, 0.25%
South Africa, 1, 0.25%
Kosovo, 1, 0.25%
Show all (47 more)
20
40
60
80
100
120
140
160
180
200